621 related articles for article (PubMed ID: 20964454)
1. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
Croxtall JD; Keam SJ
Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
[TBL] [Abstract][Full Text] [Related]
3. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
[TBL] [Abstract][Full Text] [Related]
4. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Bolli G; Dotta F; Colin L; Minic B; Goodman M
Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
[TBL] [Abstract][Full Text] [Related]
5. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2014 Apr; 74(5):587-610. PubMed ID: 24638989
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.
Rosenstock J; Fitchet M
Int J Clin Pract Suppl; 2008 Mar; (159):15-23. PubMed ID: 18269437
[TBL] [Abstract][Full Text] [Related]
7. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
8. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
Bosi E; Dotta F; Jia Y; Goodman M
Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
[TBL] [Abstract][Full Text] [Related]
9. Update: vildagliptin for the treatment of Type 2 diabetes.
Garber AJ; Sharma MD
Expert Opin Investig Drugs; 2008 Jan; 17(1):105-13. PubMed ID: 18095923
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
11. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
Foley JE; Sreenan S
Horm Metab Res; 2009 Dec; 41(12):905-9. PubMed ID: 19705345
[TBL] [Abstract][Full Text] [Related]
14. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Schweizer A; Dejager S; Bosi E
Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
[TBL] [Abstract][Full Text] [Related]
15. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Hassanein M; Abdallah K; Schweizer A
Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
Kikuchi M; Haneda M; Koya D; Tobe K; Onishi Y; Couturier A; Mimori N; Inaba Y; Goodman M
Diabetes Res Clin Pract; 2010 Sep; 89(3):216-23. PubMed ID: 20537746
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
19. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Yang LP
Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
